False-positive Aspergillus antigen testing due to application of piperacillin/tazobactam--is it still an issue?

Olaf Penack1, Patricia Rempf, Barbara Graf

  • 1Hematology and Oncology, Campus Benjamin Franklin, D-12200 Berlin, Germany. penacko@mskcc.org

Insights

False-positive galactomannan enzyme immunoassay (GEI) results from piperacillin/tazobactam (PT) therapy can be prevented. Blood draws before PT administration and separate IV sites minimize interference, ensuring accurate diagnostic testing.

Area of Science:

  • Clinical Microbiology
  • Infectious Diseases
  • Diagnostic Immunology

Background:

  • Piperacillin/tazobactam (PT) is a widely used antibiotic.
  • Galactomannan enzyme immunoassay (GEI) is a key diagnostic test for invasive fungal infections.
  • Potential interference of PT with GEI testing requires investigation.

Purpose of the Study:

  • To assess the impact of piperacillin/tazobactam (PT) therapy on the accuracy of galactomannan enzyme immunoassay (GEI).
  • To identify strategies for mitigating PT-related interference in GEI results.

Main Methods:

  • Evaluation of galactomannan content in various PT batches.
  • Analysis of GEI test results in relation to PT administration timing and site.
  • Comparison of GEI results obtained with different blood sampling and antibiotic administration protocols.

Main Results:

  • Significant variability in galactomannan content was observed across different PT batches.
  • False-positive GEI results were associated with PT administration.
  • Implementing blood sampling prior to PT administration and using separate administration sites effectively prevented false positives.

Conclusions:

  • Piperacillin/tazobactam therapy can interfere with galactomannan enzyme immunoassay testing.
  • Pre-administration blood sampling and distinct administration sites are crucial for accurate GEI results.
  • These procedural adjustments are recommended to maintain the diagnostic utility of GEI in patients receiving PT.

Related Concept Videos

Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Automated Microbial Diagnostics01:24

Automated Microbial Diagnostics

Automated diagnostic analyzers have transformed clinical microbiology by providing rapid and reliable methods for pathogen identification and antibiotic susceptibility testing. Among these systems, the Vitek 2 is widely used because it automates the traditionally labor-intensive processes of microbial identification (ID) and antibiotic susceptibility testing (AST), delivering standardized and timely results that are essential for effective patient care.Microbial Identification with ID CardsThe...